Phase III Trials Test First-Line Options in Advanced NSCLC

Abstract: Presented at the 2026 World Conference on Lung Cancer, two phase III trials—PAPILLON and REZILIENT3—established amivantamab and zipalertinib combination therapies as effective first-line strategies for advanced NSCLC with EGFR exon 20 insertions, with significantly improved progression-free survival, although high crossover rates prevented them demonstrating an overall survival benefit. Separately, HARMONi-2 showed that the bispecific antibody ivonescimab improved overall survival versus pembrolizumab in PD-L1–positive NSCLC, supporting its use as standard of care in China while larger global trials continue.